One NTLA-2002 dose lowers rate of monthly HAE attacks by 98%
NTLA-2002, the investigational gene-editing therapy from Intellia Therapeutics, reduced the number of monthly swelling attacks by a mean of 98% among people with hereditary angioedema (HAE) who were treated in the Phase 1 portion of an ongoing Phase 1/2 clinical trial. The one-time treatment also led to sustained,…